Cancer’s Sugar Coating Offers Clues for Diagnosis and Targeted Treatment
en-GBde-DEes-ESfr-FR

Cancer’s Sugar Coating Offers Clues for Diagnosis and Targeted Treatment

17.11.2026 Compuscript Ltd

A review published in Genes & Diseases highlights how changes to sugar molecules on cancer cells could help tumours grow, spread, resist treatment, and evade immune attack. Researchers at Shandong Provincial Hospital, affiliated to Shandong First Medical University, examine abnormal sialylation and its potential to guide cancer diagnosis and the development of targeted therapies.
Sialylation is the process of adding sialic acids to sugar chains attached to proteins and fats. These molecules help regulate normal cell communication and biological functions. In cancer, however, their abundance and arrangement can change, altering how tumour cells interact with tissues and the immune system.
The review brings together evidence across solid tumours and blood cancers, including gastric, colorectal, breast, lung, and pancreatic cancers, as well as leukaemia and multiple myeloma. It examines two enzyme groups that control this process: sialyltransferases, which add sialic acids, and neuraminidases, which remove them. Disruption of this balance can influence tumour behaviour.
One important mechanism involves immune evasion. Sialic acids displayed on tumour cells can engage receptors called Siglecs on immune cells, sending signals that suppress anticancer responses. This interaction creates opportunities for therapies designed to interrupt those signals or remove sialic acids from tumour surfaces.
The article also explores links between abnormal sialylation and drug resistance. Studies reviewed suggest that changes in the enzyme ST6Gal1 can affect responses to treatments such as trastuzumab in gastric cancer. Other findings connect altered sialylation with resistance in colorectal cancer and leukaemia, supporting further investigation into combinations with existing treatments.
Potential approaches include sialyltransferase inhibitors, antibodies targeting Siglecs, and antibody–sialidase conjugates that direct sugar-removing enzymes towards cancer cells. Engineered immune cells and proteins that recruit T cells while modifying tumour surface sugars also show promise in experimental models.
Beyond treatment, sialylation patterns could provide biomarkers for detecting cancer, assessing disease progression, or predicting treatment response. The review describes analytical technologies, including mass spectrometry and molecular imaging approaches, that could help researchers identify these patterns more precisely.
Important challenges remain. Sialylation also supports healthy tissues, and broad inhibition has caused liver and kidney dysfunction in animal studies. Its effects differ between cancers, with some findings suggesting protective roles. Developing selective treatments and validating biomarkers are therefore essential.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
# # # # # #
Reference
Ran Kong, Cong Wang, Yu Zhang, Guangcai Zhong, Jiarui Liu, Xiangxiang Zhou, Aberrant sialylation in cancer: From molecular mechanisms to potential therapeutics, Genes & Diseases, Volume 13, Issue 6, 2026, 102080, https://doi.org/10.1016/j.gendis.2026.102080

Funding
National Natural Science Foundation of China 82570247
National Natural Science Foundation of China 82170189
Shandong Provincial Natural Science Foundation ZR2021YQ51
Shandong Provincial Natural Science Foundation ZR2022QH204
Taishan Scholars Program of Shandong Province, China tstp20250756
Ran Kong, Cong Wang, Yu Zhang, Guangcai Zhong, Jiarui Liu, Xiangxiang Zhou, Aberrant sialylation in cancer: From molecular mechanisms to potential therapeutics, Genes & Diseases, Volume 13, Issue 6, 2026, 102080, https://doi.org/10.1016/j.gendis.2026.102080
Angehängte Dokumente
  • Sialylation on N- and O-linked glycans.
  • Timeline of sialylation development.
  • The biosynthesis pathway of sialylation.
17.11.2026 Compuscript Ltd
Regions: Europe, Ireland, United Kingdom, Asia, China
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Referenzen

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Wir arbeiten eng zusammen mit...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement